

Ulcerative Colitis [2016]: Bulletin #3

<https://marketpublishers.com/r/U8F0E5CBB79EN.html>

Date: June 2017

Pages: 0

Price: US\$ 1,045.00 (Single User License)

ID: U8F0E5CBB79EN

Abstracts

Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of ulcerative colitis (UC). Topics covered include expert opinions on: Takeda announcing the presentation of real-world analyses for Entyvio (vedolizumab) in UC; InDex Pharmaceuticals announcing that it has enrolled the first patient in the Phase IIb CONDUCT trial for Kappaproct (cobitolimod); as well as Amgen announcing the European Commission approval of Amgevita (biosimilar adalimumab) in all available indications, including moderate-to-severe UC.

Business Questions

How do KOLs regard real-world analyses of Entyvio?

What potential threats could Entyvio face in the future?

What are KOL views on Kappaproct and how would this agent be used if approved?

What impact is Amgevita/Amjevita expected to have on the UC anti-TNF market?

According to KOLs, which anti-TNF biosimilar is expected to have the most success in UC?

I would like to order

Product name: Ulcerative Colitis [2016]: Bulletin #3

Product link: <https://marketpublishers.com/r/U8F0E5CBB79EN.html>

Price: US\$ 1,045.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/U8F0E5CBB79EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970